MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00543010
First received: October 5, 2007
Last updated: June 5, 2014
Last verified: June 2014
  Purpose

A study to evaluate the cardiac and metabolic effects of MK0767 in patients with Type 2 Diabetes.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).


Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: MK0767
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Enrollment: 247
Study Start Date: November 2002
Study Completion Date: November 2003
Primary Completion Date: November 2003 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   21 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • You are taking at least one medication for high blood sugar
  • Age 21 to 80

Exclusion Criteria:

  • History of Type 1 Diabetes Mellitus
  • Currently on estrogen replacement therapy regimen
  • Currently on a weight loss program with ongoing weight loss or taking medications for weight loss
  • Having surgery 30 days before starting the study
  • Have taken any other investigational drug in the past 90 days
  • Have Hepatitis B or C
  • Active liver or gallbladder disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00543010

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00543010     History of Changes
Other Study ID Numbers: 0767-018, 2007_644
Study First Received: October 5, 2007
Last Updated: June 5, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on July 22, 2014